Catalent Pharma Solutions Supports Global Industry Response to H1N1 Flu Outbreak
Somerset, NJ, May 5, 2009
— Catalent Pharma Solutions, Inc., the leading provider of outsourced dose form manufacturing and packaging services to the global pharmaceutical, biotechnology and consumer health industry, expects to play a vital role in supporting the global pharmaceutical and biotechnology industry response to the expanding influenza A (H1N1, or swine) influenza outbreak.
Catalent has existing customer agreements to produce on demand substantial additional commercial supplies for anti-viral drugs currently recommended by the US Centers for Disease Control and Prevention to treat H1N1 type flu. Catalent is also one of the leading outsourcing providers of prefilled syringe filling for seasonal influenza vaccines at its recently opened Brussels, Belgium facility, and is preparing to deploy significant additional capacity for the multiple H1N1 flu vaccines currently being developed by its customers. Catalent also is providing advanced technologies, development services or clinical support for several compounds currently in development which are intended to prevent or treat influenza.
John Chiminski, President and CEO of Catalent, said, "Catalent is well prepared, poised and ready to help the global healthcare industry respond to the significant public health challenge that the H1N1 flu represents. We have unmatched surge capacity potential for nearly every major dose form, a broad geographic footprint, and the operational flexibility required to support the rapidly evolving industry demands."
"We are also acutely conscious of existing consumer and patient reliance on our customers, and thus on Catalent, for the thousands of other life-saving and life-enhancing products we produce every day," Chiminski continued. "We have general preparedness plans in place to address situations like the H1N1 flu, which we are constantly updating and localizing as public health situations evolve. We currently believe these plans are adequate to ensure that our customers’ products continue to be available to improve the health of people around the world."
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,400 at more than 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion in annual revenue. For more information, visit www.catalent.com .